Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity

Co-treatments to Boost IDO Activity and Inhibit Production of Downstream Catabolites Induce Durable Suppression of Experimental Autoimmune Encephalomyelitis

(2020) Henrique Lemos et al.   Frontiers in Immunology

Down Regulation of the Expression of ELMO3 by COX2 Inhibitor Suppresses Tumor Growth and Metastasis in Non-Small-Cell Lung Cancer

(2019) Cailong Pan et al.   Frontiers in Oncology

A Validation Study on IDO Immune Biomarkers for Survival Prediction in Non-small Cell Lung Cancer: Radiation Dose Fractionation Effect in Early Stage Disease

(2019) Weili Wang et al.   CLINICAL CANCER RESEARCH

Stimulator of Interferon Genes Agonists attenuate type I diabetes progression in NOD mice

(2019) Henrique Lemos et al.   IMMUNOLOGY

Metabolomic adaptations and correlates of survival to immune checkpoint blockade

(2019) Haoxin Li et al.   Nature Communications

Role of prostaglandins in tumor microenvironment

(2018) Koji Kobayashi et al.   CANCER AND METASTASIS REVIEWS

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

(2018) Maud Toulmonde et al.   JAMA Oncology

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

(2018) Andrea Botticelli et al.   Journal of Translational Medicine

Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy

(2018) Anastasia Constantinidou et al.   PHARMACOLOGY & THERAPEUTICS

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

(2018) Alexander J. Muller et al.   Seminars in Immunopathology

LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

(2018) K J Harrington et al.   ANNALS OF ONCOLOGY

Design of amidobenzimidazole STING receptor agonists with systemic activity

(2018) Joshi M. Ramanjulu et al.   NATURE

COX2/mPGES1/PGE2pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells

(2017) Victor Prima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rare Tumors in Kids May Respond to Tazemetostat

(2017)   Cancer Discovery

The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade

(2017) Howard Y. Li et al.   Cancer Immunology Research

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

(2016) Henrique Lemos et al.   CANCER RESEARCH

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response

(2016) Tiejun Li et al.   Scientific Reports

Innate Immune Recognition of Cancer

(2015) Seng-Ryong Woo et al.   Annual Review of Immunology

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

(2015) Rikke B. Holmgaard et al.   Cell Reports

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

Activation of the STING Adaptor Attenuates Experimental Autoimmune Encephalitis

(2014) H. Lemos et al.   JOURNAL OF IMMUNOLOGY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: DNA Sensing via the STING Adaptor in Myeloid Dendritic Cells Induces Potent Tolerogenic Responses

(2013) L. Huang et al.   JOURNAL OF IMMUNOLOGY

Cyclooxygenase-2 (COX-2) Inhibition Constrains Indoleamine 2,3-Dioxygenase 1 (IDO1) Activity in Acute Myeloid Leukaemia Cells

(2013) Maria Iachininoto et al.   MOLECULES

Engineering DNA Nanoparticles as Immunomodulatory Reagents that Activate Regulatory T Cells

(2012) L. Huang et al.   JOURNAL OF IMMUNOLOGY

COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps

(2011) Y. Nakanishi et al.   CARCINOGENESIS

STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity

(2009) Hiroki Ishikawa et al.   NATURE

The Immune Tolerance of Cancer is Mediated by IDO That is Inhibited by COX-2 Inhibitors Through Regulatory T Cells

(2008) Sung Yong Lee et al.   JOURNAL OF IMMUNOTHERAPY